Biomea Fusion, Inc. (BMEA) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of irreversible small molecules to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective irreversible inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.
the bull case· 2
58
managers reporting a position in filings showing institutional interest
13fJun 30 '26+10.09%
largest reporting managers increased their shares held over the latest quarter
13fJun 30 '26the bear case· 2
10
a concentrated group of managers hold most of the reported value
13fJun 30 '266 of 24
some of the largest reporting managers cut their stake in the latest quarter
13fJun 30 '26Sides and captions by the model; every figure is ours. Built Sep 16 '26 for the Nov 2 '26 report. Not a forecast, not advice.
Biomea Fusion, Inc. has no measured co-movers clearing our correlation floor, so only its SEC classification is shown.
SIC 2834, Pharmaceutical Preparations, from each company's own filings. Largest first.
tall tick = annual report · 1 on record
BMEA (Biomea Fusion, Inc.) has 1 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Suppliers:
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.
Biomea Fusion, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
High 1.90 at 3:15 pm ET, low 1.79 at 10:30 am ET.
58 managers report a position worth $38.5M between them, and 10 of them hold 80% of it.